

ONLINE MUTATION REPORT

Maternal 677CT/1298AC genotype of the *MTHFR* gene as a risk factor for cleft lip

V Shotelersuk, C Ittiwut, P Siriwan, A Angspatt

J Med Genet 2003;40:e64(<http://www.jmedgenet.com/cgi/content/full/40/5/e64>)

Non-syndromic cleft lip with or without cleft palate (CL/P) is one of the most common congenital anomalies world wide. It has a prevalence of approximately 1/1000 among white populations¹ and 1/600 among Thai newborns.² Environmental and genetic factors have been implicated in CL/P and several different loci and genes have been associated with them.³

Maternal folic acid supplementation during early pregnancy may reduce the risk for oral clefts,^{4,5} but this is controversial.⁶ One of the mechanisms by which low folate levels predispose some subjects to oral clefts could be the presence of polymorphisms in the genes encoding enzymes of the folate pathway, such as 5,10-methylenetetrahydrofolate reductase (*MTHFR*, MIM 236250). *MTHFR* catalyses the reduction of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, the predominant circulatory form of folate and the carbon donor for the remethylation of homocysteine to methionine. Two polymorphisms, 677C>T and 1298A>C, in the *MTHFR* gene have been shown to have reduced *MTHFR* activity.^{7,8} The 677C>T transition, producing an alanine to valine amino acid substitution within the catalytic domain of the *MTHFR* enzyme,⁷ has been associated with many disorders and conditions including neural tube defects,⁹ vascular disease,⁷ migraine,¹⁰ smoking behaviour,¹¹ and oral clefts.^{12,13} However, the last is controversial.¹⁴ Recent studies reported an association between the maternal polymorphism and the anomalies,^{15,16} but this again is not a consistent finding.^{17,18} No studies have investigated 1298A>C, the second most common polymorphism in *MTHFR* resulting in a glutamate to alanine substitution, in CL/P patients and their parents. We therefore carried out a case-control study to determine whether the two *MTHFR* polymorphisms in Thai patients with CL/P or their parents were associated with an increased risk of the anomaly.

SUBJECTS AND METHODS

The study sample consisted of 109 CL/P patients, 67 of their mothers, 45 of their fathers, and 202 controls. Of 109 patients, 14 were familial. All of them were studied under the auspices of the Thai Red Cross, a national charity organisation devoted to providing clinical care for the poor. Subjects were recruited between 2000 and 2002 from seven centres in Thailand (Nakornratchaseema, Nan, Uthaitanee, Maehongsorn, Trang, Srakaew, and Bangkok). As preoperative evaluations, every patient was examined by a geneticist (VS) for any presence of associated anomalies suggestive of syndromic variants. In addition, a family history and epidemiological data were obtained and will be reported elsewhere. After receiving their informed consent, blood samples for DNA analysis were obtained at the time of blood typing and haematocrit determination. Only one patient in families with more than one affected subject was included in the case group. All syndromic cases were excluded. Only the cases of non-syndromic CL/P (normal growth, normal development, and no other major anomalies) were analysed in this report.

Key points

- Previous data have shown an association between the 677C>T polymorphism in the *MTHFR* gene in either non-syndromic cleft lip with or without cleft palate (CL/P) patients or their mothers and an increased risk of the anomaly, but this finding remains controversial. No studies have investigated 1298A>C, the second most common polymorphism in *MTHFR*, in CL/P patients and their parents.
- We investigated 109 CL/P patients, 67 of their mothers, 45 of their fathers, and 202 controls for the 677C>T and 1298A>C polymorphisms. We found no association between any of the patients' genotypes and CL/P. Transmission disequilibrium test (TDT) analysis also showed no evidence for the association.
- However, a significantly higher frequency of the compound heterozygous 677CT and 1298AC genotype was detected in mothers of CL/P patients with an odds ratios of 4.43 (95% confidence interval 1.33 to 15.10).
- These results indicate an effect of the maternal genotype, rather than in the affected subjects.

The control samples were blood donors with no oral clefts in Bangkok and Nakornratchaseema collected in the same period. The study was approved by the institutional review board in Thailand.

DNA was extracted by standard procedures and was amplified using the polymerase chain reaction (PCR). Genotyping for the *MTHFR* 677C>T and 1298A>C polymorphisms was performed by restriction digestion of PCR products with *Hin*I⁷ and *Mbo*II,¹⁹ respectively.

Statistical analysis

Standard chi-square and p values were calculated by a program available at <http://quantrm2.psy.ohio-state.edu/kris/chisq/chisq.htm>. Haplotype frequencies were estimated by the EH program downloaded from <http://linkage.rockefeller.edu/ott/eh.htm>. The transmission disequilibrium test (TDT) analysis was carried out on subjects with heterozygous informative parents.²⁰ Data from families with one parent missing were excluded. Haplotypes of subjects homozygous for at least one polymorphism are readily predicted from their genotypes. All of the 677CT/1298AC genotypes were predicted to be 677C-1298C and 677T-1298A haplotypes because the 677T-1298C haplotype has not been identified.²¹ The TDT data were analysed using a $k - 1/k$ correction (where k is the number of alleles).²² Odds ratios and 95% confidence intervals (95% CI) were calculated from the Epi Info 2000 program, to estimate the relative risk of the different genotype combinations.

Table 1 Frequencies of *MTHFR* alleles in patients with CL/P, their parents, and controls

	<i>MTHFR</i> allele		χ^2 (p value)	1298A*	1298C*	χ^2 (p value)
	677C*	677T*				
CL/P patients (n=109)	0.89 (193)	0.11 (25)	0.11 (0.74)	0.72 (158)	0.28 (60)	0.05 (0.83)
Mothers (n=67)	0.83 (111)	0.17 (23)	1.97 (0.16)	0.69 (93)	0.31 (41)	0.75 (0.39)
Fathers (n=45)	0.87 (78)	0.13 (12)	0.06 (0.81)	0.79 (71)	0.21 (19)	1.22 (0.27)
Controls (n=202)	0.88 (354)	0.12 (50)	-†	0.73 (296)	0.27 (108)	-†

*The number of subjects is indicated in parentheses.

†Reference category.

Table 2 Calculated frequencies of the *MTHFR* haplotypes in patients with CL/P, their parents, and controls from the EH program

Haplotype	677C-1298A	677C-1298C	677T-1298A	677T-1298C	χ^2 *	p
CL/P patients	0.61	0.28	0.11	0.00	0.14	0.986
Mothers	0.52	0.31	0.17	0.00	3.46	0.494
Fathers	0.66	0.21	0.13	0.00	1.26	0.805
Controls	0.61	0.27	0.12	0.00	-†	-†

* $\chi^2 = 2T$; $T = (\ln(L)_{\text{case}}) + (\ln(L)_{\text{control}}) - (\ln(L)_{\text{case+control}})$.

†Reference category.

Table 3 TDT analysis in CL/P patients

Haplotype	Transmitted	Untransmitted	χ^2 *	p
677C-1298A	17	14		
677C-1298C	12	14		
677T-1298A	6	9		
677T-1298C	0	0	0.70	0.811

* χ^2 were analysed using a $k - 1/k$ correction (where k is the number of alleles). Degree of freedom = (number of rows - 1) \times (number of columns - 1) = $1 \times 2 = 2$.

RESULTS

The observed frequencies of the 677C, 677T, 1298A, and 1298C alleles in affected subjects, their mothers, their fathers, and controls are given in table 1. The observed distribution of genotypes among controls was compared with that expected according to Hardy-Weinberg equilibrium: no difference was found (for the 677 locus, $\chi^2=0.314$, 2 df, $p=0.855$; for the 1298 locus, $\chi^2=0.032$, 2 df, $p=0.984$). All genotype frequencies of the patients and their parents also followed Hardy-Weinberg equilibrium (data not shown).

The haplotype frequencies of the patients, their parents, and controls calculated from the EH program are shown in table 2. All of the 677CT/1298AC genotypes were expected to be 677C-1298C and 677T-1298A haplotypes. No 677T-1298C haplotype was found. TDT analysis was carried out on subjects with heterozygous informative parents, but it showed no evidence for association of CL/P with any of the haplotypes, as shown in table 3. In addition, the TDT analysis of each individual polymorphism did not show any association between the variant and CL/P (data not shown).

Analyses were carried out to estimate the risk associated with each genotype. The results calculated as odds ratios and 95% CI are reported in table 4. Interestingly, a significantly higher frequency of the 677CT/1298AC genotype was observed in the mothers of CL/P patients compared to controls, with an odds ratio of 4.43, 95% CI 1.33 to 15.10. The odds ratios for any other genotypes in any groups were not increased.

DISCUSSION

We have established *MTHFR* genotypes in 109 CL/P patients, their parents (67 mothers and 45 fathers), and 202 controls. The frequency of the 677T allele in our controls was 12%,

which is comparable to the frequencies of 14% in the control population reported in independent studies in Thailand.²³ Our results agree with a previous observation that the polymorphism was found in every population tested and its frequency among Asians is quite similar to that of Europeans, but higher than in Africans.²⁴ The frequency of the 1298C allele in our controls was 27%, which is similar to that of white populations (27-33%).^{8, 25}

No 677T-1298C haplotype was detected. This finding agrees with an observation that a subject with the 677TT genotype always had a 1298AA genotype and a subject with the 1298CC genotype always had a 677CC genotype (table 4). In addition, it supports the recent finding that the 677T occurred on a founder haplotype of 1298A.²¹

We found no association between any of the patients' genotypes and CL/P. TDT analysis was carried out on subjects with heterozygous informative parents but also showed no evidence for the association. This finding is consistent with a previous report.¹⁴ However, when we analysed maternal genotypes and CL/P in their offspring, we found the odds ratio calculated for mothers having the 677CT/1298AC genotype, compared to the normal 677CC/1298AA genotype, were 4.43 (95% CI 1.33 to 15.10). There were approximately 12% (eight of 67) of mothers with such a genotype; therefore, folate supplementation in a pregnant woman's diet may benefit these 12% of Thai children who are susceptible to CL/P owing to the 677CT/1298AC genotype in their mother. No such relationship could be found with any genotypes in fathers of affected offspring. This observation is in agreement with two recent independent association studies showing that there is an association between a maternal polymorphism, 677C>T, in the *MTHFR* gene in mothers of affected subjects and an increased risk of CL/P with risk ratios of 2.51 (1.00 to 6.14)¹⁵ and 4.09 (1.32 to 11.57).¹⁶

A previous study showed that the activity of the *MTHFR* enzyme in subjects with 677CT/1298AC (47.7%) is higher than that of 677TT/1298AA (24.8%).⁸ However, we found that the detected risk of the 677TT/1298AA mothers was no higher than that of the 677CT/1298AC mothers. Although the higher risk is associated with the 677TT/1298AA mothers compared to the normal 677CC/1298AA controls (odds ratio = 3.08), it is not statistically significant (95% CI 0.30 to 31.28). A possible interpretation is that the lower activity of the enzyme increases the susceptibility to fetal loss²⁶ or to giving birth to children with multiple associated malformations, without

Table 4 Prevalence and calculated odds ratios with 95% CI of the *MTHFR* polymorphisms in patients with CL/P, their parents, and controls

<i>MTHFR</i> 677/1298 genotype	Observed frequency*†				Odds ratio (95% CI)‡		
	CL/P patients (n=109)	Mothers (n=67)	Fathers (n=45)	Controls (n=202)	CL/P patients	Mothers	Fathers
CC/AA	0.30 (33)	0.25 (17)	0.42 (19)	0.33 (66)	0.89 (0.52 to 1.52)	0.70 (0.36 to 1.36)	1.51 (0.74 to 3.06)
CC/AC	0.41 (45)	0.37 (25)	0.31 (14)	0.37 (74)	1.22 (0.73 to 2.01)	1.03 (0.56 to 1.89)	0.78 (0.37 to 1.64)
CC/CC	0.06 (6)	0.06 (4)	0.04 (2)	0.07 (14)	0.78 (0.26 to 2.26)	0.85 (0.23 to 2.91)	0.62 (0.09 to 3.05)
CT/AA	0.20 (22)	0.16 (11)	0.16 (7)	0.20 (40)	1.02 (0.55 to 1.90)	0.80 (0.36 to 1.74)	0.75 (0.28 to 1.91)
CT/AC	0.03 (3)	0.12 (8)	0.02 (1)	0.03 (6)	0.92 (0.18 to 4.26)	4.43 (1.33 to 15.10)	0.74§
CT/CC	NO	NO	NO	NO	ND	ND	ND
TT/AA	NO	0.03 (2)	0.04 (2)	0.01 (2)	ND	3.08 (0.30 to 31.28)	4.65 (0.45 to 47.82)
TT/AC	NO	NO	NO	NO	ND	ND	ND
TT/CC	NO	NO	NO	NO	ND	ND	ND

*The number of subjects is indicated in parentheses. †NO = not observed. ‡ND = not determined. §The 95% CI is not determined owing to the invalidity of the Cornfield 95% confidence limits for odds ratio.

increasing the risk of CL/P alone. Another explanation would be a limited number of mothers with the 677TT/1298AA genotype in our study owing to its low frequency. Although not statistically significant, a higher risk is associated with the 677TT/1298AA fathers compared to the normal 677CC/1298AA controls (odds ratio = 4.65), which is also greater than that observed for the 677TT/1298AA mothers. Further studies with more numbers of fathers are needed to determine the association.

Three previous studies, however, showed no association between the maternal 677TT genotype and CL/P.^{17,18,27} Our results do not contradict these reports because the three studies did not determine the genotype at the 1298 position. Moreover, the inconsistent result could be caused by the difference in populations studied with diverse genetic backgrounds and environmental factors. In addition, the timing of sample collections, whether it was before or after folic acid fortification of foods, started in the USA in 1998, could affect the frequencies of the polymorphisms in subjects with some anomalies.²⁸

These findings indicate a possible involvement of the folate pathway in the causation of CL/P, and support an influence of the maternal genotype, rather than an effect of the embryo's genotype. The 677C>T polymorphism converts an alanine to a valine residue at position 222 making the *MTHFR* thermolabile with reduced activity to 65% in heterozygotes and 30% in homozygotes.⁷ The 1298A>C changes a glutamate into an alanine residue and reduces the enzyme activity to 83% in heterozygotes and 61% in homozygotes. Although neither the homozygous nor the heterozygous state for the 1298A>C is associated with raised plasma homocysteine or decreased plasma folate levels, the combined heterozygosity for 677C>T and 1298A>C is associated with higher homocysteine and lower plasma folate concentrations.⁸ Nonetheless, the real detailed biological mechanism remains to be elucidated.

So far, this is the first report on the investigations of both 677C>T and 1298A>C polymorphisms in the *MTHFR* gene of patients with CL/P and their parents. Our results indicate an effect of the maternal genotype, rather than that of the affected subjects.

ACKNOWLEDGEMENTS

We wish to thank the patients and their families for their participation in the study, and the medical staff of the Thai Red Cross, the Craniofacial Centre of King Chulalongkorn Memorial Hospital, and the Provincial Hospitals of Nakornratchasema, Nan, Uthaitance, Mae-hongsorn, Trang, and Srakaew for their excellent care of their patients. This work was supported by grants from the Thailand Research Fund, the National Center for Genetic Engineering and Biotechnology, and the Molecular Biology Projects, Faculty of Medicine, Chulalongkorn University.

Authors' affiliations

V Shotelersuk, C Itiwut, Division of Medical Genetics and Metabolism, Department of Paediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand
P Siriwan, A Angspatt, Division of Plastic Surgery, Department of Surgery, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand

Correspondence to: Dr V Shotelersuk, Division of Medical Genetics and Metabolism, Department of Paediatrics, Sor Kor Building 11th Floor, King Chulalongkorn Memorial Hospital, Bangkok 10330, Thailand; vorasuk.s@chula.ac.th

REFERENCES

- Derijcke A, Eerens A, Carels C. The incidence of oral clefts: a review. *Br J Oral Maxillofac Surg* 1996;**34**:488-94.
- Chuangsuwanich A, Aojanepong C, Muangsombut S, Tongpiw P. Epidemiology of cleft lip and palate in Thailand. *Ann Plast Surg* 1998;**41**:7-10.
- Spritz RA. The genetics and epigenetics of orofacial clefts. *Curr Opin Pediatr* 2001;**13**:556-60.
- Shaw GM, Lammer EJ, Wasserman CR, O'Malley CD, Tolarova MM. Risks of orofacial clefts in children born to women using multivitamins containing folic acid preconceptionally. *Lancet* 1995;**346**:393-6.
- Tolarova M, Harris J. Reduced recurrence of orofacial clefts after periconceptional supplementation with high-dose folic acid and multivitamins. *Teratology* 1995;**51**:71-8.
- Hayes C, Werler MM, Willett WC, Mitchell AA. Case-control study of periconceptional folic acid supplementation and oral clefts. *Am J Epidemiol* 1996;**143**:1229-34.
- Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. *Nat Genet* 1995;**10**:111-13.
- van der Put NM, Gabreels F, Stevens EM, Smeitink JA, Trijbels FJ, Eskes TK, van den Heuvel LP, Blom HJ. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? *Am J Hum Genet* 1998;**62**:1044-51.
- van der Put NM, Eskes TK, Blom HJ. Is the common 677C>T mutation in the methylenetetrahydrofolate reductase gene a risk factor for neural tube defects? A meta-analysis. *Q J Med* 1997;**90**:111-15.
- Kowa H, Yasui K, Takeshima T, Urakami K, Sakai F, Nakashima K. The homozygous C677T mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for migraine. *Am J Med Genet* 2000;**96**:762-4.
- Johnson W, Spychala J, Stenroos E, Scholl T, Schroeder C. Smoking behavior and the C677T allele of the methylenetetrahydrofolate reductase (*MTHFR*) gene. *Am J Med Genet* 2001;**98**:361-2.
- Mills JL, Kirke PN, Molloy AM, Burke H, Conley MR, Lee YJ, Mayne PD, Weir DG, Scott JM. Methylenetetrahydrofolate reductase thermolabile variant and oral clefts. *Am J Med Genet* 1999;**86**:71-4.
- Wyszynski DF, Diehl SR. Infant C677T mutation in *MTHFR*, maternal periconceptional vitamin use, and risk of nonsyndromic cleft lip. *Am J Med Genet* 2000;**92**:79-80.
- Shaw GM, Rozen R, Finnell RH, Todoroff K, Lammer EJ. Infant C677T mutation in *MTHFR*, maternal periconceptional vitamin use, and cleft lip. *Am J Med Genet* 1998;**80**:196-8.
- Martinelli M, Scapoli L, Pezzetti F, Carinci F, Carinci P, Stabellini G, Bisceglia L, Gombos F, Tognon M. C677T variant form at the *MTHFR* gene and CL/P: a risk factor for mothers? *Am J Med Genet* 2001;**98**:357-60.
- Prescott NJ, Winter RM, Malcolm S. Maternal *MTHFR* genotype contributes to the risk of non-syndromic cleft lip and palate. *J Med Genet* 2002;**39**:368-9.

- 17 **Blanton SH**, Kollé BS, Hecht JT, Mulliken JB, Martin ER. No evidence supporting MTHFR as a risk factor in the development of familial NSCLP. *Am J Med Genet* 2000;**92**:370-1.
- 18 **Gaspar DA**, Pavanello RC, Zatz M, Passos-Bueno MR, Andre M, Steman S, Wyszynski DF, Mاتيولli SR. Role of the C677T polymorphism at the MTHFR gene on risk to nonsyndromic cleft lip with/without cleft palate: results from a case-control study in Brazil. *Am J Med Genet* 1999;**87**:197-9.
- 19 **van der Put NM**, Blom HJ. Neural tube defects and a disturbed folate dependent homocysteine metabolism. *Eur J Obstet Gynecol Reprod Biol* 2000;**92**:57-61.
- 20 **Lidral AC**, Romitti PA, Basart AM, Doetschman T, Leysens NJ, Daack-Hirsch S, Semina EV, Johnson LR, Machida J, Burds A, Parnell TJ, Rubenstein JL, Murray JC. Association of MSX1 and TGFB3 with nonsyndromic clefting in humans. *Am J Hum Genet* 1998;**63**:557-68.
- 21 **Rosenberg N**, Murata M, Ikeda Y, Opare-Sem O, Zivelin A, Geffen E, Seligsohn U. The frequent 5,10-methylenetetrahydrofolate reductase C677T polymorphism is associated with a common haplotype in whites, Japanese, and Africans. *Am J Hum Genet* 2002;**70**:758-62.
- 22 **Spielman RS**, Ewens WJ. The TDT and other family-based tests for linkage disequilibrium and association. *Am J Hum Genet* 1996;**59**:983-9.
- 23 **Angchaisuksiri P**, Pingsulhiwong S, Sura T, Aryuchai K, Busabaratana M, Atichartakarn V. Prevalence of the C677T methylenetetrahydrofolate reductase mutation in Thai patients with deep vein thrombosis. *Acta Haematol* 2000;**103**:191-6.
- 24 **Schneider JA**, Rees DC, Liu YT, Clegg JB. Worldwide distribution of a common methylenetetrahydrofolate reductase mutation. *Am J Hum Genet* 1998;**62**:1258-60.
- 25 **Infante-Rivard C**, Rivard GE, Yotov WV, Genin E, Guiguet M, Weinberg C, Gauthier R, Feoli-Fonseca JC. Absence of association of thrombophilia polymorphisms with intrauterine growth restriction. *N Engl J Med* 2002;**347**:19-25.
- 26 **Zetterberg H**, Regland B, Palmer M, Ricksten A, Palmqvist L, Rymo L, Arvanitis DA, Spandidos DA, Blennow K. Increased frequency of combined methylenetetrahydrofolate reductase C677T and A1298C mutated alleles in spontaneously aborted embryos. *Eur J Hum Genet* 2002;**10**:113-18.
- 27 **Blanton SH**, Patel S, Hecht JT, Mulliken JB. MTHFR is not a risk factor in the development of isolated nonsyndromic cleft lip and palate. *Am J Med Genet* 2002;**110**:404-5.
- 28 **Johanning GL**, Wenstrom KD, Tamura T. Changes in frequencies of heterozygous thermolabile 5,10-methylenetetrahydrofolate reductase gene in fetuses with neural tube defects. *J Med Genet* 2002;**39**:366-7.